CHICAGO, ILLINOIS --- JUNE 19, 2017 --- Firma Clinical Research, an ISO quality management-certified clinical research organization (CRO), announced its launch and official unveiling at the Drug Information Association (DIA) 2017 Conference in Chicago, Illinois, June 18-22, 2017. The new company combines the expertise of Pharma Start and H20 Clinical, two clinical service organizations previously working in close collaboration, following an investment with management by Thompson Street Capital Partners, a St. Louis-based private equity firm. Built on decades of clinical development leadership and expertise, Firma Clinical supports the drug development efforts of pharmaceutical and biotech companies through advanced in-home patient visits, data management & biostatistics, medical writing, regulatory consulting, clinical pharmacology, and clinical operations. The executive team at Firma Clinical is led by:
The newly-formed Board of Directors consists of Chairman, Stephen Sullivan, Founder, CRO Advisors, LLC, Matt Scherrer, Managing Director, Thompson Street Capital Partners, Eugenia Henry, Chrissy Fleming, and Earl Henry. “We’re passionate about providing our clients with the highest-quality experience for every project we take on,” said Fleming. “We’re excited to apply that passion, knowledge, and flexibility by working side-by-side with our clients as partners to advance medicine and treatments to improve human lives.” “Our new brand and singular organization structure formalizes our unique approach to solving challenges and serving our clients in clinical development. This corporate transformation is the reflection of the collaboration and support that inspires our team to continue advancing the development of work with our clients on all of our projects,” Eugenia Henry added. Firma will be exhibiting at DIA in booth #1548. Contact us to schedule a time to meet with a team member and learn how our support can facilitate your team in making informed decisions that lead to better development outcomes. For additional information, please call 888.330.1726 or contact us at info@firmaclinical.com.
About Firma Clinical Research
An ISO 9001:2015 quality-certified organization, Firma Clinical provides focused CRO services enabling pharmaceutical and biotech clients to plan for and advance research in the drug development landscape. This support enables clients to make informed decisions that lead to better outcomes. Firma is dedicated to a collaborative approach that accelerates the development of safe and effective treatments for the pharmaceutical, biotechnology, and medical device industries. The company offers a wide array of tailored processes and services across all phases of clinical development, strategically focusing on flexible solutions, transparent communication, and on-time deliverables. For more information, please visit www.firmaclinical.com.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.